Evidence map›Paper›PMID 26067233›Full record

ArticleScientific reports2015

Preferential Amplification of Pathogenic Sequences.

Fang Ge, Jayme Parker, Sang Chul Choi, Mark Layer, Katherine Ross, Bernard Jilly, Jack Chen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Application of next generation sequencing for the detection of human viral pathogens in clinical specimens.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2017
    Article
  4. Review
  5. Viral metagenomics and blood safety.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2016
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fang GeDepartment of Biology and Wildlife, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA.
Jayme Parker1] Department of Biology and Wildlife, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA [2] Alaska State Public Health Virology Laboratory, Fairbanks, Alaska, USA.
Sang Chul ChoiDepartment of Biology and Wildlife, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA.
Mark LayerDepartment of Biology and Wildlife, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA.
Katherine RossAlaska State Public Health Laboratories, Anchorage, Alaska, USA.
Bernard JillyAlaska State Public Health Laboratories, Anchorage, Alaska, USA.
Jack Chen1] Department of Biology and Wildlife, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA [2] Alaska State Public Health Virology Laboratory, Fairbanks, Alaska, USA.
University of Alaska Fairbanks · USAlaska Department of Health and Social Services · US

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI BRIAN M BARNES · 2012 to 2026
$66.1M
Tracking and EvaluationU54GM104944 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI ZHU, YILIANG · 2013 to 2023
$39.6M
NIGMS NIH HHS P20 GM103395NIGMS NIH HHS P20GM103395NIGMS NIH HHS U54 GM104944NIGMS NIH HHS U54GM104944
6 · The paper itself

Abstract

The application of next generation sequencing (NGS) technology in the diagnosis of human pathogens is hindered by the fact that pathogenic sequences, especially viral, are often scarce in human clinical specimens. This known disproportion leads to the requirement of subsequent deep sequencing and extensive bioinformatics analysis. Here we report a method we called "Preferential Amplification of Pathogenic Sequences (PATHseq)" that can be used to greatly enrich pathogenic sequences. Using a computer program, we developed 8-, 9-, and 10-mer oligonucleotides called "non-human primers" that do not match the most abundant human transcripts, but instead selectively match transcripts of human pathogens. Instead of using random primers in the construction of cDNA libraries, the PATHseq method recruits these short non-human primers, which in turn, preferentially amplifies non-human, presumably pathogenic sequences. Using this method, we were able to enrich pathogenic sequences up to 200-fold in the final sequencing library. This method does not require prior knowledge of the pathogen or assumption of the infection; therefore, it provides a fast and sequence-independent approach for detection and identification of human viruses and other pathogens. The PATHseq method, coupled with NGS technology, can be broadly used in identification of known human pathogens and discovery of new pathogens.

Indexed as

Virus DiseasesAdenoviridaeCell Line, TumorDNA, ViralHepacivirusHerpesvirus 8, HumanHumansInfluenza A virusNucleic Acid Amplification TechniquesParainfluenza Virus 1, HumanDNA, Viral

Identifiers

PMID26067233
PMCPMC4464073
OpenAlexW2254741427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.